Roll out CD4 testing; Cryptococcal testing and treatment for AHD patients;

·      Mapping and optimization of the CD4 testing through the already existing mechanism to improve baseline CD4 testing. This has moved testing for CD4 from 50,359 to 96,964 leading to 92.5% increase.

·      Cryptococcal Meningitis testing among the PLHIV with a CD4 below 200 cells/mm³ has increased from 26,918 to 31,095.

·      Rationalization of the already existing treatment for cryptococcal meningitis this is to ensure that all the level 5 and 6 facilities are equipped to treat the disease.

·      CHAI in collaboration with the ministry of health, NASCOP, has worked on the inclusion of 5FC and AmBisome in quantification and have received product commitment for the products in COP 23. The use of this product will start in the second quarter of this year.

·      A clearly mapping of the spoke and hub model has been established for the management of complex AHD cases.

We still have CD4 POC lateral flow pending introduction. Evaluation planned to be done in the 1^st quarter of 2024 after which the role out will happen in 2^nd quarter of 2024